



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Fritz Sieber, et al.
Serial No.: 10/701,870
Filed: November 5, 2003
For: METHOD OF MAKING, AND THE USE OF CYTOTOXIC
AGENTS CONTAINING ELEMENTAL SELENIUM
Group Art Unit: 1653
Examiner: Tsay, Marsha
Ref. No.; 650053.91649

DECLARATION UNDER 37 C.F.R. §1.132

Commissioner For Patents
Alexandria, VA 22313-1450

Dear Sir:

I, Fritz Sieber, on oath say and declare that:

1. I am the same Fritz Sieber who is one of the named inventors of the above-identified patent application. I am currently employed as a Professor of Pediatrics and Medicine at the Medical College of Wisconsin, a position that I have held since 1985 (Associate Professor) and 1990 (Full Professor), respectively. I obtained my Ph.D (Dr sc nat ETH) degree in Biology in 1976 from the Swiss Federal Institute of Technology in Zurich. I have worked as a research scientist specializing in the general area of cancer research for 30 years. For the last 18 years, my research has focused on selenomercocyanine photosensitizers and their cytotoxic photoproducts (elemental selenium). I have published extensively in the area. A copy of my Curriculum Vitae is attached as Exhibit A.

2. I have reviewed the Office Action issued in this matter by the U.S. Patent and Trademark Office on April 28, 2006. I understand that claims 2, 4-6, 8, and 9 are rejected as being anticipated by Lou et al. (Clinical Chemistry 39:619-624, 1993) and claims 7 and 10-12 are rejected as being obvious over Lou et al. in view of Zhang et al. (BioFactors 15:27-38, 2001), in part because of the Examiner's concern that the inventors have not provided evidence on the size of the Se(0) particles produced and tested by the inventors. This Declaration is submitted to

provide evidence that the Se(0) particles produced and tested by the inventors have diameters of about 0.4 nm to about 1 nm.

3. Currently, it is difficult to measure Se(0) particles of 1.8 nm or smaller directly because the resolution of standard electron microscopy combined with energy dispersive X-ray analysis (EDX) is about 1.8 nm. Therefore, unlike Zhang et al. who were able to directly measure the Se(0) particles of 20-60 nm they produced by electron microscopy, we estimated the size of the Se(0) particles we produced by indirect evidence. Nevertheless, as provided below, the conclusion is scientifically sound.

4. We collaborated with Dr. William D. James (Texas A&M University) and Dr. JoAn Hudson (Clemson University) who conducted chemical and electron microscopy (resolution: 1.8 nm) analyses on our Se composition. The chemical analysis performed by inductively coupled plasma mass spectroscopy (ICP-MS) shows that our composition contains selenium in the predicted amounts. It also shows that the selenium is not removed by dialysis (molecular weight cutoff: 7 kDa), indicating that the selenium is firmly associated with the macromolecular fraction. The electron microscopic analysis, which had a resolution of 1.8 nm, failed to reveal discrete particles of selenium, indicating that the selenium moiety in our Se(0)-selenium conjugates had a diameter of less than 1.8 nm.

5. We determined from dose-response experiments that Se(0) particles bound to the mercaptalbumin molecules in our Se composition have 6 to 8 Se atoms (see sections 6-9 below for details). Se₆ and Se₈ rings (i.e., Se(0) particles with 6 and 8 Se atoms, respectively) are well known stable structures of Se(0) in the art (see e.g., Ralph A. Zingaro and W. Charles Cooper (Eds): Selenium, The Van Nostrand Reinhold Company, New York, 1974; and Takahashi T et al., Physical Review B (Condensed Matter) 28:4893-4895, 1983). By molecular modeling in Chem3D Pro (CambridgeSoft, Cambridge, MA), a software program widely used in the art and proved to be effective with many chemicals for 3-dimensional modeling, we found in consistency with the above literature as well as the chemical and electron microscopy (resolution: 1.8 nm) analyses that Se₆ or Se₈ forms a ring structure that resembles a slightly distorted doughnut with the largest diameter being about 1 nm and the smallest diameter being about 0.4 nm. Based on the above evidence, we concluded that the Se(0) particles we produced are from about 0.4 nm to about 1 nm.




6. The dose-response experiments to which section 5 refers are described in detail below. At my discretion and under my supervision, members of my laboratory conducted the following experiments:

7. Experiment A: Equal concentrations (26 μ M) of a selenomercocyanine dye were photobleached in tissue culture medium that contained equal concentrations (26 μ M) of either native bovine serum albumin or carboxymethylated albumin obtained from a commercial source (Sigma, St Louis, MO). The photobleached solutions were subsequently assayed for cytotoxic activity by *in vitro* clonal assay using L1210 leukemia cells as targets. Only dye that was photobleached in the presence of native albumin generated cytotoxic activity. Dye that was photobleached in the presence of carboxymethylated albumin did not generate cytotoxic activity. The significance of this finding is as follows. Virtually all known albumins (including human and bovine albumin) contain 35 cysteine residues. Thirty-four of the 35 cysteines form disulfide bonds. Only one cysteine (CySH-34) is present as a free thiol. In carboxymethylated albumin, CySH-34 is specifically blocked. Failure to generate cytotoxic activity in the presence of carboxymethylated albumin thus indicates that the free thiol at CySH-34 is essential for the formation of cytotoxic Se(0)-protein conjugates. The fact that blockage of a single site completely prevents the formation of cytotoxic activity also argues that multiple atoms of selenium interact as a single entity (e.g., cyclic molecule of 6-8 Se atoms) with a single site (CySH-34) rather than as individual Se atoms with a multitude of sites.

8. Experiment B: To corroborate the critical role of CySH-34 in the formation of cytotoxic Se(0)-protein conjugates, we co-incubated target cells with cytotoxic conjugates and a low dose of the anti-cancer drug cisplatin (CDDP). Cisplatin is known to react covalently with CySH-34. As Fig. 27 of this application shows, cisplatin antagonized the cytotoxic activity of Se(0)-protein conjugates, most likely by displacing Se(0) from CySH-34. For experimental details please see legend to Fig. 27.


9. Experiment C: To determine how many Se atoms combined with albumin, graded concentrations of a selenone dye were mixed with a fixed concentration of albumin, photobleached, and assayed for cytotoxic activity as described in Fig. 7 of the application. As Fig. 7 shows, a dye:protein molar ratio of about 4.5:1 was saturating. Taking into consideration the crucial role of CySH-34 in the formation of cytotoxic activity and the fact that in commercial preparations of serum albumin such as the one used for this experiment, the actual free thiol concentration is



only about 0.7 M/M, an apparent saturating dose of 4.5:1 suggests that mercaptalbumin binds about 6-8 Se atoms (most likely in the form of Se₆ and/or Se₈) whereas the non-mercaptalbumin molecules bind none.

10. I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated this 18th day of September, 2006.



Fritz Sieber

QBMKE\650053.91649\5931242.2

CURRICULUM VITAE

Fritz Sieber, PhD

- Office Address:** Medical College of Wisconsin
Department of Pediatrics
8701 Watertown Plank Road
Milwaukee, Wisconsin 53226
Tel (414) 456-4155
FAX (414) 456-6543
E-mail: fsieber@mcw.edu
- Education:**
- 1966 Matura, Kantonsschule Zug
 - 1971 Dipl Natw ETH (MS), Swiss Federal Institute of Technology, Zürich. Thesis on purification and characterization of octanol dehydrogenase and elucidation of its role in the development of *Drosophila*. Adviser: Heinrich Ursprung, PhD
 - 1976 Dr sc nat ETH (PhD), Swiss Federal Institute of Technology, Zürich. Thesis on the purification and characterization of human erythropoietin and its interactions with erythroid progenitor cells. Adviser: Heinrich Ursprung, PhD
- Postgraduate Training and Fellowship Appointments:**
- 1976-1979 Swiss National Science Foundation Fellow, Department of Biology, The Johns Hopkins University, Baltimore. Research on cell-cell recognition and adhesion. Adviser: Saul Roseman, PhD
- Faculty Appointments:**
- 1979-1985 Assistant Professor of Medicine, The Johns Hopkins University School of Medicine, Baltimore
 - 1980-1985 Assistant Professor of Oncology, The Johns Hopkins University School of Medicine, Baltimore
 - 1985-1990 Associate Professor of Pediatrics (Hematology/Oncology), Medical College of Wisconsin, Milwaukee
 - 1986- Joint appointments in Department of Cell Biology, Neurobiology & Anatomy, Department of Microbiology & Molecular Genetics, and Biophysics Program
 - 1990-1992 Professor of Pediatrics (Hematology/Oncology), Medical College of Wisconsin, Milwaukee
 - 1992- Professor of Pediatrics & Medicine (Cancer and Blood Diseases) with Tenure, Medical College of Wisconsin, Milwaukee

Awards and Honors:

1966	Willy Beusch-Prize, Zug
1976	Swiss National Science Foundation Fellowship
1977	Swiss National Science Foundation Fellowship
1978	Scholarship for Advanced Young Scientists from Swiss National Science Foundation
1980	Hubert E and Anne E Rogers Award
1984	Leukemia Society of America Scholar
1987	Frederick Stohlman Memorial Award of the Leukemia Society of America

Membership in Professional Societies:

1974-	Union of Swiss Societies of Experimental Biology
1975-	International Society for Differentiation
1978-	American Association for the Advancement of Science
1978-	American Society for Cell Biology
1979-	International Society for Experimental Hematology
	1982: Member, Organizing Committee, Annual Meeting
	1982: Session Chairman
	1991: Co-organizer and co-chairman, Satellite Symposium on Photobiology and Photomedicine
1974-	New York Academy of Sciences
1980-	Society of General Physiologist
1980-	International Society of Developmental Biologists
1981-	American Society of Hematology
	1983: Session Chairman
1982-	American Federation for Clinical Research
1982-	Society for Analytical Cytology
1983-	International Association for Comparative Research on Leukemia and Related Diseases
1985-	American Society for Photobiology
	1994: Session Chairman
	1997: Symposium Organizer
1986-	Pediatric Oncology Group
1987-	American Association for Cancer Research
1990-	International Photodynamic Association
	2006: Scientific Committee, 11th World Congress
	2007: Session Chair, 11th World Congress
1993-	International Society for Hematotherapy & Graft Engineering
1997-	American Chemical Society

Editorial Boards:

1987-1992	Associate editor, Cancer Therapy and Control
1992-2002	Editorial board, Cancer Research, Therapy & Control
1997-2002	Section editor, Cancer Research, Therapy & Control
2006-	Editorial board, Current Chemical Biology
1985-	Ad hoc reviewer for Blood, Cancer Research, Experimental Hematology, Bone Marrow Transplantation, Photochemistry and Photobiology, Transfusion, Proceedings of the National Academy of Sciences USA, British Journal of Cancer, Transplantation, Leukemia Research, Biochimica et Biophysica Acta, Journal of Photochemistry & Photobiology, Laboratory Investigation, International Journal of Radiation Biology, Archives of Biochemistry and Biophysics, Clinical Cancer Research, International Journal of Cancer, Cancer Detection and Prevention, Anatomical Record, Biology of Blood and Marrow Transplantation, Free Radical Biology and Medicine, Molecular Cancer Therapeutics, Acta Pharmacologica Sinica.

National Advisory Committees and Activities:

1985-1988	Ad hoc member, Experimental Therapeutics Study Section, NIH
1985-1986	Ad hoc reviewer, Veterans Administration
1987	Member, Organizing Committee, Leukemia Society of America 4th Annual Meeting
1990	Ad hoc reviewer, American Red Cross
1992	Ad hoc reviewer, Alberta Heritage Foundation for Medical Research
1994	Member, Special Emphasis Review Panel, National Heart, Lung, and Blood Institute
1994	Organizer, Symposium "Advances in Photodynamic Therapy and the Fluorescence Detection of Small Tumors"
1995	Experimental Therapeutics-1 Study Section, NIH
1996	Ad hoc reviewer, Veterans Administration
1997	Ad hoc reviewer, Medical Research Council of Canada
1998	Ad hoc reviewer, Hematology Study Section, NIH
2000	Member, Special Emphasis Review Panel, Experimental Therapeutics-2 Study Section, NIH

Community Advisory Committees and/or Activities:

Board member and chairman Special Gifts Committee, American Cancer Society-Milwaukee
 Member, Peer Review Committee, American Heart Association-Wisconsin Affiliate

Invited Lectures, Workshops and Site Visits:

Invited Lectures

- | | |
|-------|--|
| | <i>2005</i> |
| 01/22 | Photonics West, BiOS 2005, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy. San Jose, CA. |
| | <i>2004</i> |
| 02/24 | Inaugural Plenary Lecture, 9th International Conference on the Chemistry of Selenium and Tellurium (ICCST-9), Bombay, India. |
| | <i>2003</i> |
| 08/12 | National Cancer Institute, Rockville, MD |
| | <i>1999</i> |
| 07/15 | Immunotech SA, Marseille, France |
| | <i>1998</i> |
| 02/12 | University of Wisconsin-Madison, School of Engineering, Wisconsin Center for Space Automation and Robotics, Madison, WI. |
| 06/22 | Theratechnologies, Inc. and McGill University, Montreal, Canada |
| | <i>1997</i> |
| 07/05 | Workshop "Photopheresis: Paradigms and Mechanisms"
25th Annual Meeting of the American Society for Photobiology,
St. Louis, MO |
| 07/09 | Symposium "New Developments in Extracorporeal Photochemotherapy"
25th Annual Meeting of the American Society for Photobiology,
St. Louis, MO |
| 10/24 | University of Wisconsin-Madison, School of Pharmacy, Madison, WI. |
| | <i>1996</i> |
| 01/11 | Space Technology and Applications International Forum, Albuquerque, NM |
| | <i>1995</i> |
| 05/06 | Fourth Great Lakes PDT Conference, Detroit, MI |
| | <i>1994</i> |
| 02/10 | The Temple University Cancer Center, Philadelphia, PA. |
| 09/19 | Symposium "Advances in Photodynamic Therapy and the Fluorescence Detection of Small Tumors", Children' Hospital of Wisconsin, Milwaukee, WI |
| | <i>1993</i> |

- 06/29 Symposium on Photochemical Blood Sterilization, 21st Annual Meeting of the American Society for Photobiology, Chicago, IL
- 09/17 4th International on Bone Marrow Purging and Processing, Orlando, FL
- 1992*
- 05/27 Symposium on DNA Cleavage and Viral Inactivation, American Chemical Society Regional Meeting, Cincinnati, OH
- 06/24 Symposium on the Sterilization of Blood by Light, 20th Annual Meeting of the American Society for Photobiology, Marco Island, FL
- 09/10 11th International Congress on Photobiology, Kyoto, Japan
- 1991*
- 06/24 Symposium on the Photoinactivation of Viruses and Cells for Medical Applications, 19th Annual Meeting of the American Society for Photobiology, San Antonio, TX
- 07/27 Satellite Symposium on Photobiology and Photomedicine, 20th Annual Meeting of the International Society for Experimental Hematology, Parma, Italy
- 09/03 4th Congress of the European Society for Photobiology, Amsterdam, The Netherlands
- 11/02 6th Annual Meeting of the Clinical Immunology Society, Arlington, VA
- 1990*
- 01/20 SPIE Think Tank on the Future of Photodynamic Therapy, San Diego, CA
- 03/26 Therapeutic Immunology Inc, Minneapolis, MN
- 06/20 Annual Meeting, American Society for Photobiology, Vancouver, BC
- 06/21 Photodynamic Therapy Workshop, University of British Columbia, Vancouver, BC
- 10/04 The James Graham Brown Cancer Center, University of Louisville, Louisville, KY
- 1989*
- 01/05 Quadra Logic Technologies and University of British Columbia, Vancouver, BC, Canada
- 03/20 Wayne State University, Detroit, MI
- 07/20 18th Annual Meeting, International Society for Experimental Hematology, Paris, France
- 12/05 31st Annual Meeting, American Society of Hematology, Atlanta, GA
- 1988*
- 04/06 Eastman Pharmaceuticals, Great Valley, PA
- 06/15 Leukemia Society of America-Wisconsin
- 07/20 Sterling Research Group, Malvern, PA
- 08/20 4th International Symposium on Autologous Bone Marrow Transplantation, Houston, TX
- 09/07 Advances in Photochemotherapy, Boston, MA
- 10/27 Sterling Research Group, Malvern, PA

1987

02/13 First International Workshop on Bone Marrow Purging, Orlando, FL
 02/17 Photodynamic Therapy Conference, Marina del Rey, CA
 03/05 The New York Blood Center, New York, NY
 03/19 Third National Leukemia Society of America Symposium, San Diego, CA
 10/09 St. Jude Children's Research Hospital, Memphis, TN
 10/29 Conference on New Directions in Photodynamic Therapy, Cambridge, MA

1986

01/14 Memorial Sloan-Kettering Cancer Center, New York, NY
 02/13 Developmental and Clinical Investigation Program, Sloan-Kettering Institute, New York, NY
 07/07 Eastman-Kodak Company, Rochester, NY
 10/11 Wisconsin Dermatological Society

1985

02/12 Upstate Medical Center, Syracuse, NY
 03/06 The Upjohn Company, Kalamazoo, MI
 07/09 Autologous Bone Marrow Transplant Meeting, Parma, Italy
 11/07 Second International Symposium on Detection and Treatment of Minimal Residual Disease in Leukemia, Rotterdam, The Netherlands

Site Visits

1994

03/22 National Cancer Institute, program project grant (Case Western Reserve University, Cleveland, OH)

1993

02/22-02/24 National Cancer Institute, program project grant (Case Western Reserve University, Cleveland, OH)

1990

03/07 National Cancer Institute, program project grant (Case Western Reserve University)

1989

06/05-06/07 National Cancer Institute, program project grant (University of Toledo, Medical College of Ohio, Wayne State University, University of Michigan Ann Arbor).

BIBLIOGRAPHY

ORIGINAL PAPERS

1. Sieber F, Fox DJ and Ursprung H: Properties of octanoldehydrogenase from *Drosophila*. FEBS Letters 26:274-276, 1972.
2. Madhavan K, Conscience-Egli M, Sieber F and Ursprung H: Farnesol metabolism in *Drosophila melanogaster*: ontogeny and tissue distribution of octanoldehydrogenase and aldehyde oxidase. J Insect Physiol 19:235-241, 1973.
3. Iscove NN, Sieber F and Winterhalter KH: Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin-A. J Cell Physiol 83:309-320, 1974.
4. Iscove NN and Sieber F: Erythroid progenitors in mouse bone marrow detected by macroscopic colony formation in culture. Exp Hematol 3:32-43, 1975.
5. Sieber F: Chromatography of human urinary erythropoietin and granulocyte colony stimulating factor on insolubilized phytohaemagglutinin. Biochim Biophys Acta 496:146-154, 1977.
6. Sieber-Blum M, Sieber F and Yamada KM: Cellular fibronectin promotes development of quail neural crest cells in vitro. Exp Cell Res 133:285-295, 1981.
7. Sieber F, Meagher RC and Spivak JL: Differential sensitivity of mouse hematopoietic stem cells to merocyanine 540. Differentiation 19:65-67, 1981.
8. Sieber F and Roseman S: Quantitative analysis of intercellular adhesiveness in freshly explanted and cultured cells. J Cell Biol 90:55-62, 1981.
9. Sieber F, Stuart RK and Spivak JL: Tumor-promoting phorbol esters stimulate myelopoiesis and suppress erythropoiesis in cultures of mouse bone marrow cells. Proc Natl Acad Sci USA 78:4402-4406, 1981.
10. Sieber-Blum M and Sieber F: Tumor-promoting phorbol esters promote melanogenesis and prevent expression of the adrenergic phenotype in quail neural crest cells. Differentiation 20:117-123, 1981.
11. Kuhlenschmidt MS, Schmell E, Slife CW, Kuhlenschmidt TB, Sieber F, Lee, YC and Roseman S: Studies on the intercellular adhesion of rat and chicken hepatocytes: conditions affecting cell-cell specificity. J Biol Chem 257:3157-3164, 1982.

12. Sieber F and Sharkis SJ: Modulation of murine erythropoiesis in vitro by syngeneic thymocytes: interactions of enhancing and suppressing subpopulations with fluorescent anti-theta antibody and polyamino acids. *Blood* 60:845-849, 1982.
13. Meagher RC, Sieber F and Spivak JL: Suppression of hematopoietic progenitor cell proliferation by ethanol and acetaldehyde. *N Engl J Med* 307:845-849, 1982.
14. Dover GJ, Chan T and Sieber F: Fetal Hemoglobin production in cultures of primitive and mature human erythroid progenitors. Differentiation affects the quantity of fetal hemoglobin produced per cell not the number of fetal hemoglobin-containing cells. *Blood* 61:1242-1246, 1983.
15. Meagher RC, Sieber F and Spivak JL: Susceptibility to merocyanine 540-mediated photosensitization: a differentiation marker on murine hematopoietic progenitor cells. *J Cell Physiol* 116:118-124, 1983.
16. LaRussa VF, Sieber F, Sensenbrenner LL and Sharkis SJ: Effects of neuraminidase on the regulation of erythropoiesis. *Blood* 63:784-788, 1984.
17. Sieber-Blum M. and Sieber F.: Heterogeneity among early quail neural crest cells. *Develop Brain Res* 14:241-246, 1984.
18. Sieber F, Spivak JL and Sutcliffe AM: Selective killing of leukemic cells by merocyanine 540-mediated photosensitization. *Proc Natl Acad Sci USA* 81:7584-7587, 1984.
19. Sieber F and Sieber-Blum M: Dye-mediated photosensitization of murine neuroblastoma cells. *Cancer Res* 46:2072-2076, 1986.
20. Sieber F, Rao S, Rowley SD and Sieber-Blum M: Dye-mediated photolysis of human neuroblastoma cells: Implications for autologous bone marrow transplantation. *Blood* 68:32-36, 1986.
21. Levine RF, Spivak JL, Meagher RC and Sieber F: Effect of ethanol on thrombopoiesis. *Br J Haematol* 62:345-354, 1986.
22. Sieber F, Stuart RK, Rowley SD, Sharkis SJ and Sensenbrenner LL: Dye-mediated photolysis of normal and neoplastic hematopoietic cells. *Leukemia Res* 11:43-49, 1987.
23. Sieber F.: Elimination of residual tumor cells from autologous bone marrow grafts by dye-mediated photolysis: preclinical data. *Photochem Photobiol* 46:71-76, 1987.
24. Kalyanaraman B, Feix JB, Sieber F, Thomas JP and Girotti AW: Photodynamic action of merocyanine 540 on artificial and natural cell membranes: Involvement of singlet molecular oxygen. *Proc Natl Acad Sci USA* 84:2999-3003, 1987.

25. Sieber F, O'Brien JM, Krueger GJ, Schober SL, Burns WH, Sharkis SJ and Sensenbrenner LL: Antiviral activity of merocyanine 540. *Photochem Photobiol* 46:707-711, 1987.
26. Sieber F, Krueger GJ, O'Brien JM, Schober SL, Sensenbrenner LL and Sharkis SJ: Inactivation of Friend erythroleukemia virus and Friend virus-transformed cells by merocyanine 540-mediated photosensitization. *Blood* 73:345-350, 1989.
27. O'Brien JM and Sieber F: Mutagenicity of merocyanine 540-mediated photosensitization. *Exp Hematol* 17:166-170, 1989.
28. Sieber F and Krueger GJ: Photodynamic therapy and bone marrow transplantation. *Sem Hematol* 26:35-39, 1989.
29. Gaffney DK, Schober SL and Sieber F: Merocyanine 540-sensitized photoinactivation of leukemia cells: Role of oxygen and effects on plasma membrane integrity and mitochondrial respiration. *Exp Hematol* 18:23-26, 1990.
30. Smith OM and Sieber F: Antineoplastic and virucidal effects of merocyanine 540. *Trends in Photochemistry & Photobiology* 1:49-59, 1990.
31. O'Brien JM, Montgomery RR, Burns WH, Gaffney DK and Sieber F: Evaluation of merocyanine 540-sensitized photoirradiation as a means to inactivate enveloped viruses in blood products. *J Lab Clin Med* 116:439-447, 1990.
32. Gaffney DK and Sieber F: Merocyanine 540-sensitized photoinactivation of soluble and membrane-bound enzymes in L1210 leukemia cells. *Cancer Res* 50:7765-7769, 1990.
33. Gaffney DK, O'Brien JM and Sieber F: Modulation by thiols of the merocyanine 540-sensitized photolysis of leukemia cells, red cells, and herpes simplex virus type 1. *Photochem Photobiol* 53:85-92, 1991.
34. Smith OM, Traul DL, McOlash L and Sieber F: Evaluation of merocyanine 540-sensitized photoirradiation as a method for purging malarially-infected red cells from blood. *J Infect Diseases* 163:1312-1317, 1991.
35. Lum LG, Yamagami M, Giddings BR, Joshi I, Schober SL, Sensenbrenner LL and Sieber F: The immunoregulatory effects of merocyanine 540 on in vitro human T and B lymphocyte functions. *Blood* 77:2701-2706, 1991.
36. Smith OM, Gaffney DK, Anderson MS, McOlash L, Schober SL and Sieber F: Plasma membrane properties regulating the sensitivity of leukemia, lymphoma, and solid tumor cells to merocyanine 540-sensitized photoirradiation. *Exp Hematol* 19:785-788, 1991.

37. Gaffney DK, Feix JB, Schwarz HP, Struve MF and Sieber F: Cholesterol content but not plasma membrane fluidity influences the susceptibility of L1210 leukemia cells to merocyanine 540-sensitized irradiation. *Photochem Photobiol* 54:717-723, 1991.
38. O'Brien JM, Singh RJ, Feix JB, Kalyanaraman B and Sieber F: Action spectra of the antileukemic and antiviral activities of merocyanine 540. *Photochem Photobiol* 54:851-854, 1991.
39. Itoh T, Gaffney DK, and Sieber F: Merocyanine 540 as a marrow purging agent: Split addition of dye in two half-doses reduces toxicity to normal hematopoietic stem cells without reducing the antineoplastic effect. *Cancer Ther Contr* 2:251-258, 1992.
40. Whelan HT, Traul DL, Przybylski C, Segura A, Thomas J, Meyer G and Sieber F: Interactions of merocyanine 540 with human brain tumor cells. *Ped Neurol* 8:117-120, 1992.
41. Qiu K, Traul DL and Sieber F: Limited cell-cycle dependence of the merocyanine 540-sensitized photoinactivation of L1210 leukemia cells. *Photochem Photobiol* 56:277-280, 1992.
42. Qiu K and Sieber F: Merocyanine 540-sensitized photoinactivation of leukemia cells: Effects of dose fractionation. *Photochem Photobiol* 56:489-493, 1992.
43. O'Brien JM, Gaffney DK, Wang TP and Sieber F: Merocyanine 540-sensitized photoinactivation of enveloped viruses in blood products: Site and mechanism of phototoxicity. *Blood* 80:277-285, 1992.
44. Smith OM, Dolan SA, Dvorak JA, Wellems TE and Sieber F: Merocyanine 540-sensitized photoinactivation of human erythrocytes parasitized by *Plasmodium falciparum*. *Blood* 80:21-24, 1992.
45. Smith OM, Traul DL and Sieber F: Photodamaging effects of merocyanine 540 on neutrophils and HL-60 cells. *Exp Hematol* 20:1278-1284, 1992.
46. Gaffney DK and Sieber F: The role of serum and serum components in the merocyanine 540-sensitized photoinactivation of K562 leukemia cells. *Biochim Biophys Acta* 1117:321-325, 1992.
47. Smith OM, Qiu K, Witt PL, Borden EC and Sieber F: Merocyanine 540 and two-phase partitioning detect interferon- β_{ser} -induced plasma membrane alterations in Daudi lymphoma cells. *Cancer Res Ther Contr* 3:87-93, 1993.
48. Qiu K and Sieber F: Pharmacokinetics of merocyanine 540. *Cancer Res Ther Contr* 3:239-243, 1993.

49. Itoh T, Messner HA, Jamal N, Tweeddale M and Sieber F: Merocyanine 540-sensitized photoinactivation of high-grade non-Hodgkin's lymphoma cells: Potential application in autologous bone marrow transplantation. *Bone Marrow Transpl* 12:191-196, 1993.
50. Krieg M, Bilitz JM, Traul DL and Sieber F: Photosensitizing oxonol dyes with antineoplastic activity. *Cancer Res Ther Contr* 4:163-172, 1995.
51. Traul DL, Anderson GS, Bilitz JM, Krieg M and Sieber F: Potentiation of Merocyanine 540-mediated photodynamic therapy by salicylate and related drugs. *Photochem Photobiol* 62:790-199, 1995.
52. Anderson GS, Günther WHH, Searle R, Bilitz JM, Krieg M and Sieber F: Inactivation of photosensitizing merocyanine dyes by plasma, serum, and serum components. *Photochem Photobiol* 64:683-687, 1996.
53. Yamazaki T and Sieber F: The alkyl-lysophospholipid, ET-18-OCH₃ synergistically enhances the Merocyanine 540-mediated photoinactivation of leukemia cells: Implications for the extracorporeal purging of autologous hematopoietic stem cells. *Bone Marrow Transpl* 19:113-119, 1997.
54. Yamazaki T and Sieber F: Effect of hypothermia on the Merocyanine 540-mediated purging of hematopoietic cells. *J Hematother* 6:31-39, 1997.
55. Yamazaki T, Sato Y and Sieber F: Role of cytoprotective mechanisms in the photochemical purging of autologous bone marrow grafts. *Exp Hematol* 25:629-637, 1997.
56. Kubo Y and Sieber F: Photochemical purging of autologous bone marrow grafts: Assessment of damage to stem cells and the microenvironment in long-term marrow cultures. *Bone Marrow Transpl* 20:27-31, 1997.
57. Sato Y, Daziano J-P and Sieber F: Photochemical purging of autologous stem cell grafts: Potentiation of the antileukemic activity of Merocyanine 540 by ethacrynic acid. *Cancer Res Ther Contr* 5:241-251, 1998.
58. Indig GL, Anderson GS, Nichols MG, Barlett JA, Mellon WS and Sieber F: Effect of molecular structure on the performance of triarylmethane dyes as therapeutic agents for photochemical purging of autologous bone marrow grafts from residual tumor cells. *J Pharm Sci* 89:88-99, 2000.
59. Tsujino I and Sieber F: Genetic variability in the response of normal murine hematopoietic progenitor cells to extracorporeal photochemotherapy. *Photochem Photobiol* 72:810-814, 2000.

60. Tsujino I, Anderson GS and Sieber F: Post-irradiation hyperthermia selectively potentiates the Merocyanine 540-sensitized photoinactivation of small cell lung cancer cells. *Photochem Photobiol* 73:191-198, 2001.
61. Anderson GS, Miyagi K, Sampson RW and Sieber F: Anti-tumor effect of Merocyanine 540-mediated photochemotherapy combined with Edelfosine: Potential implications for the ex vivo purging of hematopoietic stem cell grafts from breast cancer patients. *J Photochem Photobiol B: Biology* 68:101-108, 2002.
62. Anderson GS, Tsujino I, Miyagi K, Sampson RW and Sieber F: Preferential inactivation of paediatric solid tumour cells by sequential exposure to Merocyanine 540-mediated photodynamic therapy and Edelfosine: Implications for the ex vivo purging of autologous haematopoietic stem cell grafts. *J Photochem Photobiol B: Biology* 69:87-95, 2003.
63. Miyagi K, Sampson RW, Sieber-Blum M and Sieber F: Crystal violet and Merocyanine 540 for the ex vivo purging of hematopoietic stem cell grafts. *J Photochem Photobiol B: Biology* 70:133-144, 2003.
64. Tsujino I, Miyagi K, Sampson RW and Sieber F: Potentiation of the anti-tumor effect of Merocyanine 540-mediated photodynamic therapy by amifostine and amphotericin B. *Photochem Photobiol*, 82:458-465, 2006.

CHAPTERS AND REVIEWS

1. Iscove NN, Sieber F and Winterhalter K: Human urinary erythroid colony stimulating activity: assay in cultures of mouse and human bone marrow and similarity to erythropoietin on Sephadex and Concanavalin-A Sepharose. *In Hemopoiesis in Culture*. WA Robinson, ed. US Government Printing Office, Washington, pp 44-52, 1974.
2. Iscove NN, Sieber F and Winterhalter KH: Human urinary erythroid colony stimulating activity (E-CSA): techniques for detection in culture and chemical separations. *In Hemopoiesis in Culture*. WA Robinson, ed. US Government Printing Office, Washington, pp 421-423, 1974.
3. Sieber F: Erythroid colony growth in culture: effect of desialated erythropoietin, neuraminidase, dimethyl sulfoxide, and Amphotericin B. *In Progress in Differentiation Research*. N Muller-Bérat, ed. North Holland, Amsterdam, pp 521-528, 1976.
4. Sieber F: Cell-cell interactions. *In Advanced Cell Biology*. LM Schwartz and MM Azar, eds. Van Nostrand Reinhold, New York, pp 226-233, 1981.

5. Sieber F, Meagher RC and Spivak JL: Susceptibility to merocyanine 540-mediated photosensitization as a differentiation marker in murine hematopoietic stem cells. *In Embryonic Development, Part B: Cellular Aspects.* MM Burger and R Weber, eds. Alan R Liss, New York, pp 135-144, 1982.
6. Spivak J. and Sieber F: Erythropoietin. *In Hormones in Normal and Abnormal Human Tissues.* K Fotherby and SB Pal, eds. DeGruyter, New York, pp 63-96, 1983.
7. Sieber F, Meagher RC, Sutcliffe AM and Spivak JL: Purging of leukemic cells from bone marrow grafts by merocyanine 540-mediated photosensitization. *In Leukemia Reviews International, Vol. 1, Advances in Comparative Leukemia Research.* MA Rich and DS Yohn, eds. Marcel Dekker, New York and Basel, pp 30-31, 1983.
8. Sieber F: Merocyanine 540-mediated photosensitization of leukemia and solid tumor cells. *In Molecular Basis of Cancer, Part B: Macromolecular Recognition, Chemotherapy, and Immunology.* R Rein, ed. Alan R Liss, New York, pp 227-234, 1985.
9. Sieber-Blum M and Sieber F: In vitro analysis of quail neural crest cell differentiation. *In Cell Culture in the Neurosciences.* JE Bottenstein and G Sato, eds. Plenum, New York, pp 193-222, 1985.
10. Sieber F: Detection and selective destruction of tumor cells by the lipophilic dye, merocyanine 540. *In Minimal Residual Disease in Acute Leukemia.* A Hagenbeek and B Lowenberg, eds. Martinus Nijhoff, Boston, pp 282-294, 1986.
11. Sieber F: Dye-mediated photolysis of tumor cells: Implications for autologous bone marrow transplantation. *In Progress in Bone Marrow Transplantation.* RP Gale and R Champlin, eds. Alan R Liss, New York, pp 865-869, 1987.
12. Sieber F: Marrow purging by merocyanine 540-mediated photolysis. *Bone Marrow Transpl* 2:29-33, 1987.
13. Sieber F: Autologous bone marrow transplantation in the treatment of leukemia: Cleansing of the marrow graft. *Intern Med for the Specialist* 8:138-149, 1987.
14. Sieber F: Merocyanine 540 (yearly review). *Photochem Photobiol* 46:1035-1042, 1987.
15. Sieber F: A role for photodynamic therapy in autologous bone marrow transplantation. *In Proceedings of SPIE-The International Society of Optical Engineering, Vol 847, New Directions in Photodynamic Therapy.* DC Neckers, ed. SPIE, Bellingham, pp 148-152, 1987.

16. Itoh T, Ball ED and Sieber F: Antileukemic effect of merocyanine 540-mediated photosensitization combined with complement-mediated immune lysis and its role in the purging of autologous remission marrow grafts. *In* Bone Marrow Transplantation: Current Controversies. RP Gale and R Champlin, eds. Alan R Liss, New York, pp 301-312, 1989.
17. Sieber F: Antineoplastic and antiviral properties of merocyanine 540. *In* Proceedings of SPIE-The International Society of Optical Engineering, Vol 997, Advances in Photochemotherapy. T Hasan, ed. SPIE Optical Engineering Press, Bellingham, pp 128-131, 1989.
18. Sieber F: Merocyanine 540 as a marrow purging agent: Interactions of Merocyanine 540 with normal and neoplastic cells. *In* Autologous Bone Marrow Transplantation, Proceedings of the Fourth International Symposium. KA Dicke, G Spitzer, S Jagannath and MJ Evinger-Hodges, eds. The University of Texas MD Anderson Cancer Center, pp 763-767, 1989.
19. Sieber F: Photosensitizing agents for marrow purging in autologous bone marrow transplantation. *In* Experimental Hematology Today-1989. NC Gorin and L Douay, eds. Springer-Verlag, New York, pp 10-15, 1990.
20. O'Brien JM and Sieber F: Merocyanine 540-sensitized photoinactivation of enveloped viruses and its application in the sterilization of blood products. *In* Experimental Hematology Today-1989. NC Gorin and L Douay, eds. Springer-Verlag, New York, pp 26-30, 1990.
21. Sieber F: Photodynamic therapy and bone marrow transplantation. *In* Future Directions and Applications in Photodynamic Therapy. CJ Gomer, ed. SPIE Optical Engineering Press, Bellingham, pp 209-218, 1990.
22. Sieber F: Extracorporeal purging of bone marrow grafts by dye-sensitized photoirradiation. *In* Bone Marrow Processing and Purging: A Practical Guide. A P Gee, ed. CRC Press, Boca Raton, pp 263-280, 1991.
23. Günther WHH, Searle R and Sieber F: Structure-activity relationships in the antiviral and antileukemic photoproperties of merocyanine dyes. *Sem Hematol* 29:88-94, 1992.
24. Sieber F, O'Brien JM and Gaffney DK: Merocyanine-sensitized photoinactivation of enveloped viruses. *Blood Cells* 18:117-128, 1992.
25. Sieber F, O'Brien JM and Gaffney DK: Antiviral effects of photosensitizing merocyanine dyes: Implications for transfusion and bone marrow transplantation. *Sem Hematol* 29:79-87, 1992.
26. Günther WHH, Searle R and Sieber F: Photosensitizing merocyanine dyes based on selenobarbituric acid. *Phosphorus Sulfur and Silicon* 67:417-424, 1992.

27. Sieber F: Phototherapy, photochemotherapy and bone marrow transplantation. *J Hematotherapy* 2:43-62, 1993.
28. Sieber F, Gaffney DK, Yamazaki T and Qiu K: Importance of cellular defense mechanisms in the photodynamic purging of autologous bone marrow grafts. *In Advances In Bone Marrow Purging and Processing: Fourth International Symposium*, S Gross, AP Gee and D Worthington-White, eds. Wiley-Liss, New York, pp 147-154, 1994.
29. Sieber F: Extracorporeal photochemotherapy. *In Space Technology and Applications International Forum*, MS El-Genk, ed, American Institute of Physics Conference Proceedings 361, Woodbury, NY, pp 413-419, 1996.
30. Sieber F: Second-generation merocyanine photosensitizers for photodynamic therapy. *Trends in Photochemistry and Photobiology* 10:1-13, 2003.
31. Sieber F, Daziano J-P, Günther WHH, Krieg M, Miyagi K, Sampson RW, Ostrowski MD, Anderson GS, Tsujino I and Bula RJ: Elemental selenium generated by the photobleaching of selenomercyanine photosensitizers forms conjugates with serum macromolecules that are toxic to tumor cells. *Phosphorus Sulfur, and Silicon and the Related Elements* 180:647-657, 2005.
32. Sieber F, Daziano J-P, Sampson RW, Tsujino I, Miyagi K, Ostrowski MD, Anderson GS, Günther WHH and Krieg M: Role of photoproducts in the cytotoxic action of selenomercyanine-mediated photodynamic therapy. *In Optical Methods for Tumor Treatment and detection: Mechanisms and techniques in Photodynamic Therapy XIV*. D Kessel, ed. Proceedings of SPIE Vol 5689. The International Society for Optical Engineering, Bellingham, pp 56-65, 2005.

THESES

1. Sieber F: Biochemie und Entwicklungsbiologie von Octanoldehydrogenase in *Drosophila melanogaster*. Diplomarbeit. Eidgenössische Technische Hochschule, Zürich, 1971.
2. Sieber F: Erythropoietin und seine Wirkung auf erythropoietische Zellen. Dissertation Nr. 5678. Eidgenössische Technische Hochschule, Zürich, 1976.

EDITORIALS, LETTERS TO EDITOR

1. Deeg HJ, Sieber F and Porcellini A: Introduction: Photomedicine - to use the power of light. *Semin Hematol* 29:77-78, 1992.

ABSTRACTS

1. Sieber F, Iscove NN and Winterhalter KH: Separation of human urinary erythropoietin from glycoproteins of similar size using concanavalin A-Sepharose. *Experientia* 29:758, 1973.
2. Iscove NN and Sieber F: Macroscopic erythroid colony formation in cultures of mouse bone marrow cells. *Exp Hematol* 2:278, 1974.
3. Sieber F: Effects of sialidase and DMSO on erythroid colony growth in culture. *Experientia* 31:748, 1975.
4. Sieber F, Iscove NN and Guilbert LJ: Erythropoietin dependence of primitive and late red cell precursors in culture. *Experientia* 32:812, 1976.
5. Sieber F, Guilbert LJ and Iscove NN: Purification of erythropoietin: affinity chromatography on insolubilized phytohemagglutinin. *Fed Proc* 35:1627, 1976.
6. Schmell E, Kuhlenschmidt M, Sieber F and Roseman S: Stimulation of hepatocyte adhesion by plasma membranes (a new assay). *Fed Proc* 37:1501, 1978.
7. Sieber-Blum M, Sieber F, Yamada KM and Cohen AM: Cell surface fibronectin (FN) in cultures of differentiating neural crest cells. *J Cell Biol* 79:31a, 1978.
8. Sieber F and Roseman S: Assay of intercellular adhesive specificity in transformed and mutant cell lines. *Experientia* 35:979, 1979.
9. Sieber F, Sieber-Blum M and Roseman S: Quantitative analysis of intercellular adhesion in embryonic chick muscle. *J Cell Biol* 83:60a, 1979.
10. Sieber F, Sharkis SJ and Spivak JL: Characterization of anti-theta sensitive regulatory cells (TSRC) by surface charge using the fluorescence activated cell sorter. *Exp Hematol* 8:S7, 62, 1980.
11. Sensenbrenner LL, Sharkis SJ, Spivak LL, Sieber F and Stuart RK: Isolation of erythroid progenitor cells from bone marrow using fluoresceinated wheat germ agglutinin. *Exp Hematol* 8:S7, 128, 1980.
12. Sieber F and Spivak JL: Differential sensitivity of mouse hematopoietic progenitor cells to merocyanine 540. *Europ J Cell Biol* 22:416, 1980.
13. Sieber-Blum M and Sieber F: Tumor-promoting phorbol ester affects neural crest cell development. *Europ J Cell Biol* 22:407, 1980.

14. Sieber F, Stuart RK and Spivak JL: Dual effect of tumor-promoting phorbol esters on mouse hematopoietic progenitor cells. *J Cell Biol* 87:18a, 1980.
15. Sieber-Blum M, Sieber F and Yamada KM: Adrenergic differentiation of neural crest cells is promoted by cellular fibronectin (CFN). *J Cell Biol* 87:13a, 1980.
16. Meagher RC, Sieber F and Spivak JL: Suppression of hematopoietic progenitor cells by ethanol and acetaldehyde. *Exp Hematol* 9:S9, 137, 1981.
17. Sieber F, Meagher RC, Sensenbrenner LL, Sharkis SJ and Spivak JL: Susceptibility to merocyanine 540-mediated photolysis as a differentiation marker in murine and human hematopoietic stem cells. *Exp Hematol* 9:S9, 149, 1981.
18. Meagher RC, Sieber F and Spivak JL: Preferential suppression of erythroid progenitor cells by ethanol and acetaldehyde. *Clin Res* 29:A340, 1981.
19. Sieber F, Stuart RK, Sensenbrenner LL and Sharkis SJ: Susceptibility to merocyanine 540-mediated photolysis as a differentiation marker in human hematopoietic stem cells. *Blood* 58:102a, 1981.
20. Dover GJ, Chan T and Sieber F: Both early and late erythroid progenitors produce increased levels of HbF in culture. *Blood* 58:67a, 1981.
21. Meagher RC, Sieber F and Spivak JL: Preferential suppression of human erythroid colony formation by ethanol. *Blood* 58:99a, 1981.
22. Meagher RC, Sieber F and Spivak JL: Interaction of mouse marrow macrophages with early with early and late erythroid progenitor cells. *Clin Res* 30:324A, 1982.
23. Sieber F, Stuart RK, Sensenbrenner LL, Sharkis SJ and Spivak JL: Merocyanine 540-mediated photosensitization preferentially inhibits in vitro colony formation by two leukemia cell lines. *Clin Res* 30:331A, 1982.
24. LaRussa VF, Sieber F, Sensenbrenner LL and Sharkis SJ: The effect of neuraminidase on hematopoietic stem cells (CFU-s, BFU-e, CFU-e, and CFU-c) and /or thymic regulatory cells. *Exp Hematol* 10:S11, 59, 1982.
25. Meagher RC, Sieber F and Spivak JL: A differentiation marker for normal murine hematopoietic progenitor cells. *Exp Hematol* 10:S11, 60, 1982.
26. Sieber F, Stuart RK, Sensenbrenner LL, Sharkis SJ and Spivak JL: Plasma membrane properties of normal human hematopoietic progenitor cells and leukemia cells. *Exp Hematol* 10:S11, 85, 1982.
27. Dover GJ, Chan T and Sieber F: Both early and late erythroid progenitors produce increased levels of HbF in culture. *Exp Hematol* 10:S11, 163, 1982.

28. Sieber-Blum M and Sieber F: Plasma membrane heterogeneity in early avian neural crest cells. *J Cell Biol* 95:43a, 1982.
29. Sieber F, Meagher RC, Sutcliffe AM and Spivak JL: Purging of leukemic cells from bone marrow grafts by merocyanine 540-mediated photosensitization. *Clin Res* 31:412A, 1983.
30. Meagher RC, Levine RF, Spivak JL and Sieber F: Effect of ethanol on megakaryocyte progenitor cells and mature megakaryocytes. *Clin Res* 31:319A, 1983.
31. Sieber F, Sharkis SJ and Sieber-Blum M: Modulation of erythropoiesis by thymocytes: Effects of the culture system. *Exp Hematol* 11:S14, 29, 1983.
32. Sharkis SJ, Sieber F and Sensenbrenner LL: Cellular interactions which regulate the growth of erythroid progenitor cells in vitro. *Exp Hematol* 11:S14, 27, 1983.
33. LaRussa VF, Sieber F, Sensenbrenner LL and Sharkis SJ: In vivo effects of neuraminidase on the regulation of erythropoiesis. *Exp Hematol* 11:S14, 25, 1983.
34. Sieber F, Sharkis SJ and Sieber-Blum M: Does modulation of erythropoiesis by thymocytes depend on an adhesive substrate? *Blood* 62:127a, 1983.
35. Sieber F, Hilton J and Colvin OM: Photodynamic therapy of drug-resistant tumors. *Exp Hematol* 12:423, 1984.
36. Sieber F and Sieber-Blum M: Cell surface analysis in multilineage systems. *J. Embryo. Exp Morphol* 82:234, 1984.
37. Id J, Spivak JL, Sieber F and Noe D: An intracellular mitogen in polycythemia vera and idiopathic myelofibrosis. *Clin Res* 32:697A, 1984.
38. Sieber F and Sieber-Blum M: Purging of neuroblastoma cells from bone marrow grafts. *Clin Res* 33:458A, 1985.
39. Sieber F: Extracorporeal purging of leukemia and solid tumor cells by merocyanine 540. *Int J Cell Cloning* 3:233-234, 1985.
40. Manna A and Sieber F: Cell-cycle specificity of merocyanine 540-mediated photosensitization. *Int J Cell Cloning* 3:277-278, 1985.
41. Sieber F, Rao S, Rowley SD and Sieber-Blum M: Selective photosensitization on human neuroblastoma cells: Implications for autologous bone marrow transplantation. *Blood* 66:271a, 1985.
42. Sieber F: Dye-mediated photolysis of tumor cells: Implications for autologous bone marrow transplantation. *J Cell Biochem* S10D:220, 1986.

43. Sieber F: Elimination of residual tumor cells from autologous bone marrow grafts by dye-mediated photolysis: Preclinical data. *Photochem Photobiol* 43:106S, 1986.
44. Kalyanaraman B and Sieber F.: On the mechanism of merocyanine 540-mediated photosensitization. *Photochem Photobiol* 43:28S, 1986.
45. Sieber F, Craig A, Krueger GJ, Smith RE and Ash RC: Auto- transplantation of bone marrow after extracorporeal purging with merocyanine 540 and light. *Blood* 68:292a, 1986.
46. Sieber F: Dye-mediated photosensitization of residual tumor cells. *Leukemia* 1:248, 1987.
47. Krueger GJ, Schober SL and Sieber F.: Inactivation of solid tumor cells by merocyanine 540-mediated photolysis. *Photochem Photobiol* 45:101S, 1987.
48. Itoh T, Krueger GJ, Messner HA, Jamal N, Tweeddale M and Sieber F: Merocyanine 540-mediated photolysis of high grade non-Hodgkin's lymphoma cells. *Blood* 70:320a, 1987.
49. O'Brien JM, Schober SL, Burns WH, Krueger GJ, Montgomery RR and Sieber F: Inactivation of enveloped human pathogenic viruses by merocyanine 540-mediated photosensitization and its potential use in blood product sterilization. *Blood* 70:333a, 1987.
50. Sieber F: Detection and treatment of minimal residual disease. *Leukemia* 2:190, 1988.
51. O'Brien JM and Sieber F: Mutagenicity of merocyanine 540-mediated photosensitization. *Leukemia* 2:195, 1988.
52. Gaffney D and Sieber F: Antineoplastic effects of merocyanine 540: Role of serum and serum components. *Proc Amer Assoc Cancer Res* 29: 497, 1988.
53. Itoh T, Ball ED and Sieber F.: Inactivation of leukemia cells by sequential exposure to merocyanine 540 and cytotoxic antibodies. *J Cell Biochem* 12C:120, 1988.
54. Gaffney DK and Sieber F: Mechanistic aspects of merocyanine 540-mediated photolysis. Abstract Book, P-6, MD-PhD Conference, Aspen CO, July 22-25, 1988.
55. Kornguth S, Sieber F and Kalinke T: Photolytic effect of polylysyl-phthalocyanine derivatives on murine Neuro 2a neuroblastoma cells. Abstracts, 18th Annual Meeting of the Society for Neuroscience 14 (2): 1264, 1988.

56. Itoh T, Gaffney D and Sieber F: Ex vivo purging of bone marrow with merocyanine 540: Split addition of photosensitizer reduces toxicity to normal stem cells. *Blood* 72: 392a, 1988.
57. Martin LS, Krueger GJ, Orloff SL and Sieber F: Dye-mediated photolysis of HIV-1 and HIV-infected cells. *J Cell Biochem* S13B:282, 1989.
58. Gaffney DK and Sieber F: Binding of merocyanine 540 by cells labelled with anthroxyloxy fatty acids. *Photochem Photobiol* 49:31S, 1989.
59. Gaffney DK and Sieber F: Role of thiols in the merocyanine 540-sensitized photoinactivation of L1210 leukemia cells. Abstract Book, Workshop on Photodynamic Therapy, Boston, MA, June 29-30, 1989.
60. Smith OM and Sieber F: Partitioning of tumour cells differing in their susceptibility to merocyanine-mediated photoinactivation. *Photochem Photobiol* 49:31S, 1989.
61. Sieber F: Photosensitizing agents for marrow purging in autologous bone marrow transplantation. *Exp Hematol* 17:481, 1989.
62. O'Brien JM and Sieber F: Merocyanine 540-sensitized photoinactivation of enveloped viruses and its application in the sterilization of blood products. *Exp Hematol* 17:659, 1989.
63. O'Brien JM, Gaffney DK and Sieber F: Sterilization of blood products by merocyanine 540-sensitized photoirradiation: integrity of red cells and mechanism of action. *Blood* 74:295a, 1989.
64. Gaffney DK, Anderson MS, Traul DL and Sieber F: Merocyanine 540-sensitized photoinactivation of L1210 leukemia cells: inhibition of transport systems. *J Cell Biochem* 14A:319, 1990.
65. Sieber F, O'Brien JM and Gaffney DK: Sterilization of blood products by dye-sensitized photoirradiation. *Photochem Photobiol* 51:96S, 1990.
66. Gaffney DK, Feix JB, Schwarz HP and Sieber F: Effects of lipid modulation on the merocyanine 540-sensitized photoinactivation of L1210 leukemia cells. *Photochem Photobiol* 51:66S, 1990.
67. Gaffney DK, O'Brien JM and Sieber F: Merocyanine 540-sensitized photoinactivation of leukemia cells and enveloped viruses: mechanisms of action. Abstract Book, 3rd Biennial Meeting of the International Photodynamic Association, Buffalo, NY, July 17-21, p 17, 1990.

68. Smith OM, Traul DL, McOlash L and Sieber F: Evaluation of merocyanine 540-sensitized photoirradiation as a method for purging malarially-infected cells from donor blood. *Photochem Photobiol* 51:67S, 1990.
69. Lum LG, Yamagami M, Giddings BR, Schober SL and Sieber F: Merocyanine 540 and light inhibits T and B cell functions. *Exp Hematol* 18:560, 1990.
70. Yamagami M, Smith OM, Sieber F and Lum LG: Inhibition of T cell activation by merocyanine 540 (MC 540)-mediated photolysis. *Exp Hematol* 18:559, 1990.
71. Sieber F, O'Brien JM, Traul DL, Gaffney DK and Smith OM: Potential applications of the photosensitizer, merocyanine 540, in bone marrow transplantation. *Exp Hematol* 18:714, 1990.
72. O'Brien J, Gaffney DK and Sieber F: Modulation by thiols of the antiviral and cytotoxic effects of merocyanine 540-sensitized photoirradiation. *Blood* 76:405a, 1990.
73. O'Brien JM, Singh RJ, Feix JB, Kalyanaraman B and Sieber F: Action spectra of the antileukemic and antiviral activities of merocyanine 540. *Blood* 76:558a, 1990.
74. Smith OM, Traul DL and Sieber F: Functional integrity of human neutrophils after merocyanine 540-sensitized photoirradiation. *J Cell Biochem* 15G:40, 1991.
75. Traul DL, McOlash L, Shih C-Y and Sieber F: Merocyanine 540-sensitized photoirradiation for the prophylaxis of graft-versus-host disease? *J Cell Biochem* 15G:41, 1991.
76. Qiu K, Kania D and Sieber F: Merocyanine 540-sensitized photoinactivation of leukemia cells. Effects of dose fractionation. *Proc Amer Assoc Cancer Res* 32:389, 1991.
77. Kubo Y and Sieber F: Effects of merocyanine 540-sensitized photoirradiation on cells of the hematopoietic microenvironment. *Exp Hematol* 19:567, 1991.
78. Sieber F, Gaffney DK, O'Brien JM, Sprague WS, Smith OM, Qiu K, Kania D and Kroes RA: Cellular defense mechanisms against merocyanine 540-mediated photodynamic damages. *Exp Hematol* 19:565, 1991.
79. Sieber F, O'Brien JM and Gaffney DK: Inactivation of enveloped viruses by merocyanine 540-sensitized irradiation. *Photochem Photobiol* 53 (Supplement):55S-56S, 1991.
80. Sieber F: Merocyanine 540: Mechanism of action and potential applications in bone marrow transplantation and blood banking. Abstract Book, Fourth Congress

of the European Society for Photobiology, Amsterdam, The Netherlands, September 1-6, p 19, 1991.

81. Whelan HT, Segura A, Przybylski C, Traul D and Sieber F: Interactions of merocyanine 540 with human brain tumor cells: preferential binding in vivo and dye-sensitized photoinactivation in vitro. *Ann Neurol* 30:459, 1991.
82. Sieber F, Günther WHH, Searle R, O'Brien JM and Gaffney DK: Photosensitizing merocyanine dyes: Structure-activity relationships, Mechanisms of action, and preclinical evaluation as blood sterilizing agents. *Photochem Photobiol* 55S:114-115, 1992.
83. Sieber F, Günther WHH, Searle R, O'Brien JM and Gaffney DK: Merocyanine dyes as antiviral agents. Abstract # 107, Abstract Book, 24th Central Regional Meeting, American Chemical Society, Cincinnati, OH, May 26-29, 1992.
84. Traul DL, Smith OM and Sieber F: Effects of merocyanine 540-sensitized photoirradiation on cation homeostasis in L1210 leukemia and A549 lung carcinoma cells. *Exp Hematol* 20: 730, 1992.
85. Traul DL and Sieber F: Merocyanine 540-sensitized photoirradiation induces apoptosis in HL-60 leukemia cells. *Blood* 80:143a, 1992.
86. Sieber F, Günther WHH, Searle R, O'Brien JM, Gaffney DK, Traul DL, Schober SL, Potter D, Bilitz JM and Krieg M: Photosensitizing merocyanine dyes with antiviral and antineoplastic activity: Structure-activity relationships and photochemical and photophysical characterization. *Photochem Photobiol* 57:66S, 1993.
87. Sieber F, Gaffney DK, Yamazaki T and Qiu K: Role of cellular defense mechanisms in the photodynamic purging of autologous bone marrow grafts. Abstract Book, Fourth International Symposium on Bone Marrow Purging and Processing, Orlando, FL, September 16-17, 1993.
88. Yamazaki T and Sieber F.: Effects of temperature on the merocyanine 540-sensitized photoinactivation of leukemia and lymphoma cells. *Blood* 82:655a, 1993.
89. Yamazaki T and Sieber F: Role of cytoprotective mechanisms in the merocyanine 540-sensitized photoinactivation of leukemia and normal hematopoietic stem cells. *Proc Amer Assoc Cancer Res* 35:644, 1994.
90. Traul DL and Sieber F: Induction of apoptosis and necrosis in leukemia and solid tumor cells by merocyanine 540-mediated PDT. *Photochem Photobiol* 59:70S, 1994.

91. Traul DL, Bilitz JM, Hilliard M, Krieg M and Sieber F: Modulation of Merocyanine 540-mediated PDT by salicylate and related drugs. *Photochem Photobiol* 59:72S, 1994.
92. Yamazaki, T. and Sieber, F.: Alkyl-lysophospholipid synergistically enhances the merocyanine 540-mediated purging of leukemia cells from simulated autologous remission marrow grafts. *Blood* 84:497a, 1994.
93. Krieg M, Bilitz JM, Traul DL and Sieber F: Photosensitizing oxonol dyes with antileukemic activity. *Blood* 84:729a, 1994.
94. Krieg M, Bilitz JM and Sieber F: Synthesis and preclinical evaluation of photosensitizing oxonol dyes. *Photochem Photobiol* 61:69S, 1995.
95. Sato Y and Sieber F: Ethacrynic acid enhances the merocyanine 540-mediated purging of leukemia cells from autologous bone marrow grafts. *Blood* 86:235a, 1995.
96. Anderson GS, Gaffney DK, Bilitz JM, O'Brien JM, Krieg M, Günther WHH, Searle R and Sieber F: Photosensitizing merocyanine dyes with antileukemic activity: Superior performance of naphth[2,1-d] and selenobarbituric acid derivatives under high serum conditions. *Blood* 86:521a, 1995.
97. Anderson GS, Gaffney DK, Bilitz JM, O'Brien JM, Krieg M, Günther WHH, Searle R and Sieber F: Binding, aggregation, and stability of merocyanine photosensitizers with improved antileukemic activity. *Photochem Photobiol* 63:93S, 1996.
98. Mangan KF, Mullaney MT and Sieber F: Amifostine protects progenitor cell growth and enhances breast cancer cell death in the photolytic merocyanine purging system. Abstract Book "Novel Approaches in Blood and Marrow Transplantation", San Diego, CA, October 2-6, 1996, p 27.
99. Sato Y and Sieber F: Inhibition of aminophospholipid translocation enhances the merocyanine 540-mediated photoinactivation of leukemia cells. *Blood* 88:251b, 1996.
100. Anderson GS, Günther WHH, Searle R, Bilitz JM, Krieg M and Sieber F: Photosensitizing merocyanine dyes with antineoplastic activity: Structural requirements for resistance to degradation by plasma. *Blood* 88:147b, 1996.
101. Sato Y and Sieber F: Merocyanine 540-mediated photodynamic therapy inhibits phosphatidylserine translocation in leukemia cells. *Proc Amer Assoc Cancer Res* 38:377, 1997.

102. Daziano JP, Krieg M and Sieber F: Potential involvement of cytotoxic photoproduct in MC54-mediated photoinactivation of leukemia cells. *Photochem Photobiol* 65:59S-60S, 1997.
103. Sieber F: Photochemical purging of autologous hematopoietic stem cells: Lessons from (and for) phase I/II clinical trials. *Photochem Photobiol* 65:79S-80S, 1997.
104. Jones LR and Sieber F: Light-dependent and light-independent uptake of merocyanine 540 in leukemia cells. *Photochem Photobiol* 65:8S-9S, 1997.
105. Mangan KF, Mullaney MT and Sieber F: Amifostine protects CD34+ purified stem cells in the merocyanine photolytic purging system. *Blood* 90:374a, 1997.
106. Anderson GS and Sieber F: Combination purging with merocyanine 540 and the alkyl-lysophospholipid, Et-18-OCH₃: synergistic enhancement of the inactivation of solid tumor cells. *Blood* 90:349b, 1997.
107. Daziano JP, Anderson GS, Günther WHH, Searle R, Krieg M and Sieber F: Improved probes and simplified procedures for the quantitative assay of apoptotic cells under high-throughput conditions. *Cytometry* S9:114, 1998
108. Sieber F and Yamazaki T: Importance of cellular defense mechanisms in stem cell purging. *J Hematother* 7:286, 1998.
109. Anderson GS and Sieber F: Combination purging of pediatric solid tumors with Merocyanine 540 and ET-18-OCH₃. *J Hematother*, 7:286, 1998.
110. Daziano JP, Anderson GS, Günther WHH, Tsujino I, Krieg M, Searle R and Sieber F: Photoproduct-albumin adducts: a new class of antineoplastic agents. *Exp Hematol* 26:787, 1998.
111. Anderson GS and Sieber F: Combination purging of autologous stem cell grafts contaminated with solid tumor cells. Abstract Book, Annual Meeting of The American Society of Pediatric Hematology/Oncology, Chicago, IL, Sept 10-12, 1998, p 38.
112. Tsujino I, Anderson GS and Sieber F: Hyperthermia preferentially potentiates the Merocyanine 540-mediated photoinactivation of small cell lung carcinoma cells. *Blood* 92:319b, 1998.
113. Tsujino I and Sieber F: Selective enhancement of the antitumor effect of merocyanine 540-PDT by amphotericin B used in combination with amifostine. *Photochem Photobiol* 69: 37S, 1999.
114. Sieber F, Anderson GS and Tsujino I: Photochemical purging of stem cell grafts contaminated with solid tumor cells. *Exp Hematol* 27:128, 1999.

115. Sieber F, Daziano J-P, Tsujino I, Anderson G and Krieg M: Antileukemic activity of photoproduct-albumin adducts. Late-Braking Abstracts, LBA016, 28th Annual Meeting of The International Society for Experimental Hematology, Monte Carlo, Monaco, July 10-14, 1999.
116. Indig GL, Anderson GS, Nichols MG, Bartlett JA, Mellon WS and Sieber F: Triarylmethane dyes as therapeutic agents for the photochemical purging of autologous bone marrow grafts from residual tumor cells. *Biophys J* 78:256a, 2000.
117. Tsujino I, Bousbaa J and Sieber F: Albumin uptake defines sensitivity to selenomercyanine-derived photoproduct-albumin adducts. *Proc Amer Assoc Cancer Res* 41:700, 2000.
118. Tsujino I and Sieber F: Genetic variability in the response of normal murine hematopoietic progenitor cells to photochemical purging. *Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH)*, Tampa, FL, July 8-11, 2000, Onsite Guide, pp 54-55, 2000.
119. Daziano J-P, Bousbaa J, Tsujino I, Anderson GS, Gunther WHH, Krieg M and Sieber F: Preferential targeting of tumor cells with selenomercyanine-derived photoproduct-albumin adducts. *Europ J Cell Biol* 79 (S52): 178, 2000.
120. Miyagi K, Bousbaa J and Sieber F: Low-dose Merocyanine 540-PDT potentiates the anti-tumor effect of crystal violet-PDT. *Program and Abstract Book, 29th Annual Meeting of the American Society for Photobiology*, Chicago, IL, July 7-12, 2001, p 38, 2001.
121. Miyagi K and Sieber F: Triarylmethane dyes and Merocyanine 540 for the ex vivo purging of hematopoietic stem cells. *Proc Amer Assoc Cancer Res* 43: 650, 2002.
122. Miyagi K and Sieber F: Response of leukemia cells, solid tumor cells, drug-resistant tumor cells and normal hematopoietic progenitor cells to crystal violet and Merocyanine 540-PDT. *Program and Abstracts, 30th Annual Meeting of the American Society for Photobiology*, Quebec City, Canada, July 13-17, 2002, pp 104-105, 2002.
123. Sieber F, Daziano J-P, Anderson GS, Miyagi K, Sampson RW, Tsujino I, Gunther WHH, Krieg M, Bousbaa J and Försterling FH: Colloidal selenium generated by photobleaching of selenomercyanine dyes combines with serum macromolecules to form conjugates that are preferentially cytotoxic to leukemia and selected solid tumor cells. *Blood* 100: 224b, 2002.
124. Miyagi K, Sampson RW, Tsujino I, Gunther WHH, Krieg M and Sieber F: Proteinated subnanoparticles of elemental selenium potentiate the anti-tumor effect of ionizing radiation and selected chemotherapeutic agents. *Proc Amer Assoc Cancer Res* 44: 385, 2003.

125. Sieber F: Proteinated subnanoparticles of colloidal selenium: A new class of anti-leukemia/lymphoma agents. *Leukemia* 17: 683, 2003.
126. Sieber F: Selenium in oxidation state zero is a potent and selective anti-leukemia/lymphoma agent. *Exp Hematol* 31 (S1):119-120, 2003.
127. Sieber F, Daziano J-P, Günther WHH, Krieg M, Miyagi K, Sampson RW, Ostrowski MD, Anderson GS, Tsujino I and Bula R: Elemental selenium generated by the photobleaching of selenomercyanine photosensitizers forms conjugates with serum macromolecules that are toxic to tumor cells. Abstract Book, 9th International Conference on the Chemistry of Selenium and Tellurium (ICCST-9), Bombay, India, February 23-27, 2004, p 1, 2004.
128. Tsujino I, Miyagi K, Sampson RW, Günther WHH, Krieg M and Sieber F: Proteinated elemental selenium potentiates the anti-tumor effect of ionizing radiation and chemotherapeutic agents and is only minimally affected by drug resistance mechanisms. *Blood* 104:175b, 2004.
129. Sieber F, Daziano J-P, Sampson RW, Tsujino I, Miyagi K, Ostrowski M, Anderson GS, Günther WHH and Krieg M: Role of photoproducts in the cytotoxic action of selenomercyanine-mediated PDT. Abstract Book, Photonics West, BiOS 2005, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy, San Jose, CA, January 22-23, 2005, Abstract No. 5689-13, 2005.
130. Sieber F, Daziano J-P, Tsujino I, Miyagi K, Sampson RW, Anderson GS, Ostrowski MD, Gunther WHH and Krieg M: Proteinated elemental selenium; A novel class of anti-cancer agents. Abstract Book, International Conference on Tumor Progression and Therapeutic Resistance, Philadelphia, PA, November 8-9, 2004, p 80, 2004.
131. Sampson RW, Miyagi K, Ostrowski MD, Günther WHHG, Krieg M and Sieber F: Elemental selenium for the treatment of breast cancer. Proceedings, Era of Hope Department of Defense Breast Cancer Research Program Meeting, Philadelphia, June 8-11, 2005, p 298.
132. Daziano J-P, Gunther WHH, Krieg M, Miyagi K, Sampson RW, Ostrowski MD, Anderson GS, Tsujino I, Bula RJ and Sieber F: Elemental selenium generated by photobleaching of selone photosensitizers forms conjugates with serum proteins that are selectively cytotoxic to tumor cells. Abstract Book, Selenium 2006 - 8th International Symposium on Selenium in Biology and Medicine, Madison, WI, July 25-30, 2006, p 51, 2006.

PATENTS

1. Sieber F: Inactivating enveloped viruses with a merocyanine dye. US Patent Number 4,775,625, issued on October 4, 1988.
2. Sieber F: Antiviral method, agents and apparatus. US Patent Number 4,915,683, issued on April 10, 1990.
3. Sieber F and Smith OM: Antiprotozoan method. US Patent Number 5,039,483, issued on August 13, 1991.
4. Sieber F and Smith OM: Method of eradicating infectious biological contaminants. US Patent Number 5,304,113, issued on April 19, 1994. Licensed to Cobe/Gambro/Navigant.
5. Sieber F, Günther WHH, Daziano J-P, Krieg-Kowald M, Bousbaa J and Bula RJ: Method of making, and the use of cytotoxic agents containing elemental selenium. US Patent Application Serial Number 10/701,870, pending.
6. Sieber F, Günther WHH, Daziano J-P, Krieg-Kowald M, Bousbaa J and Bula RJ: Method of making, and the use of cytotoxic agents containing elemental selenium. Patent Cooperation Treaty US 03/35125, pending.

QBMKE\5957418.2